Antibodies prevalence against Haemophilus influenzae type b in Jeddah population, Saudi Arabia. III. Antibodies avidity

Zarei, Adi Essam; Redwan, Elrashdy M.

doi:10.3233/hab-180345

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we did find that the level of IgG2 subclass was significantly higher in patients who survived the disease compared to those who did not. Previous studies demonstrated that the IgG2 level was associated with protective immunity (Zarei and Redwan, 2019) and defense against recurrence of capsulated bacterial infections (Kralickova et al, 2017;Yamazaki et al, 2019). Follow up work includes a comparison between the intracellular bacterial growth rate of live B. ps pre-opsonized with purified IgG2 antibodies derived from survivors and nonsurvivors.…”

Section: Discussionmentioning

confidence: 99%

Serum From Melioidosis Survivors Diminished Intracellular Burkholderia pseudomallei Growth in Macrophages: A Brief Research Report

Chaichana

Kronsteiner

Rongkard

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Melioidosis is a neglected tropical disease with high mortality rate. It is caused by the Gram-negative, CDC category B select agent Burkholderia pseudomallei ( B. ps ) that is intrinsically resistant to first-line antibiotics. An antibody-based vaccine is likely to be the most effective control measure. Previous studies have demonstrated significant mechanistic roles of antibodies in protection against death in animal models, but data from human melioidosis is scarce. Herein, we used in-vitro antibody-dependent cellular phagocytosis and growth inhibition assays to assess the mechanism of protective antibodies in patients with acute melioidosis. We found that serum from patients who survived the disease enable more live B. ps to be engulfed by THP-1 derived macrophages (median 1.7 × 10 3 CFU/ml, IQR 1.1 × 10 3 -2.5 × 10 3 CFU/ml) than serum from patients who did not survive (median 1.2 × 10 3 CFU/ml, IQR 0.7 × 10 3 -1.8 × 10 3 , p = 0.02). In addition, the intracellular growth rate of B. ps pre-opsonized with serum from survivors (median 7.89, IQR 5.58–10.85) was diminished when compared with those with serum from non-survivors (median 10.88, IQR 5.42–14.88, p = 0.04). However, the difference of intracellular bacterial growth rate failed to reach statistical significance when using purified IgG antibodies ( p = 0.09). These results provide new insights into a mechanistic role of serum in protection against death in human melioidosis for antibody-based vaccine development.

show abstract

Section: Discussionmentioning

confidence: 99%